Multiple system atrophy

Seminars in Neurology

Volumn 21, Issue 1, 2001, Pages 33-40

  Wenning, G K ^a   Seppi, K ^a   Scherfler, C ^a   Stefanova, N ^a   Puschban, Z ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Differential diagnosis; Multiple system atrophy; Therapy

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AUTONOMIC DYSFUNCTION; CEREBELLAR ATAXIA; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROPATHOLOGY; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM; TREATMENT PLANNING;

EID: 0035038527     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-13117     Document Type: Review

References (69)

1. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990
2. Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study
3. Consensus statement on the diagnosis of multiple system atrophy
4. Clinical features and natural history of multiple system atrophy: An analysis of 100 cases
5. Multiple system atrophy: A review of 203 pathologically proven cases
6. Multiple system atrophy: The nature of the beast
7. Multiple system atrophy
8. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy
9. The natural history of Parkinson's disease
10. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: A clinicopathological study
11. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: A clinicopathological study
12. Clinical presentation and pharmacological therapy in corticobasal degeneration
13. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination
14. Benzodiazepine receptor binding in the cerebellum in multiple system atrophy and olivopontocerebellar atrophy studied with positron emission tomography
15. Investigation of autonomic disorders
16. Is EEG useful in the differential diagnosis of parkinsonism?
17. Genitourinary dysfunction in multiple system atrophy: Clinical features and treatment in 62 cases
18. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy
19. Clinical usefulness of magnetic resonance imaging in multiple system atrophy
20. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy
21. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy
22. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism
23. 123I] beta-CIT and SPECT: Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy
24. Disease-specific patterns of neuronal loss in the spinal ventral horn in amyotrophic lateral sclerosis, multiple system atrophy and X-linked recessive bulbospinal neuronopathy, with special reference to the loss of small neurons in the intermediate zone
25. The neuropathology and neurochemistry of multiple system atrophy
26. Progression of falls in postmortem-confirmed parkinsonian disorders
27. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy
28. The definition of multiple system atrophy: A review of recent developments
29. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology
30. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome)
31. Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease
32. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies
33. Tau immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
34. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies
35. Alpha-synuclein in Lewy bodies
36. α-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
37. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy
38. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein
39. Synucleins in synaptic plasticity and neurodegenerative disorders
40. Widespread alterations of alpha-synuclein in multiple system atrophy
41. Mice lacking α-synclein display functional deficits in the nigrostriatal dopamine system
42. Low frequency of alpha-synuclein mutations in familial Parkinson's disease
43. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
44. No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy
45. Amantadine in parkinsonian patients unresponsive to levodopa: A pilot study
46. Parkinson's disease: Second of two parts
47. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration
48. Autoradiographic study of striatal dopamine reuptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts
49. Towards neurotransplantation in multiple system atrophy: Clinical rationale, pathophysiological basis, and preliminary experimental evidence
50. Clinicopathologicai study of 35 cases of multiple system atrophy
51. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?
52. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study
53. Multiple system atrophy: Natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT
54. 123-I-iodobenzamide-SPECT dopamine D2 receptor imaging in normals, patients with Parkinson's disease and other akinetic-rigid syndromes
55. Multiple system atrophy and progressive supranuclear palsy: Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography
56. Iodine-123-epidepride-SPECT: Studies in Parkinson's disease, multiple system atrophy and Huntington's disease
57. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration
58. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease
59. 18F-FDG
60. Benzodiazepine receptor binding in the cerebellum in multiple system atrophy and olivopontocerebellar atrophy studied with positron emission tomography
61. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease
62. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
63. Positron emission tomography studies in parkinsonism
64. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography
65. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: A positron emission tomography study
66. 11C-raclopride and positron emission tomography
67. 11 NMSP and PET
68. 11C]diprenorphine PET study
69. Olivoponrocerebellar atrophy and multiple system atrophy: Clinical follow-up of 10 patients studied with PET